Frazier Financial Advisors LLC Has $73,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Frazier Financial Advisors LLC lowered its stake in AstraZeneca PLC (NASDAQ:AZN) by 24.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 935 shares of the company’s stock after selling 301 shares during the quarter. Frazier Financial Advisors LLC’s holdings in AstraZeneca were worth $73,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of AZN. McClarren Financial Advisors Inc. increased its position in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in AstraZeneca during the second quarter worth approximately $26,000. Capital Performance Advisors LLP acquired a new position in AstraZeneca during the third quarter worth approximately $28,000. Pathway Financial Advisers LLC bought a new stake in shares of AstraZeneca during the first quarter worth approximately $29,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of research analyst reports. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 2.8 %

Shares of AZN stock opened at $63.23 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. The stock has a market cap of $196.05 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The stock has a 50 day simple moving average of $75.03 and a 200 day simple moving average of $78.22. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the business earned $0.87 earnings per share. The company’s revenue was up 18.0% on a year-over-year basis. On average, research analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.